Navigation Links
Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
Date:11/3/2008

SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data from a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented next week at a satellite symposium at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans.

John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, will present the data from the multicenter, international Pre/RELAX-AHF study as part of a symposium entitled "Tailoring Therapy to Presentation" that will focus on new approaches to the treatment of acute heart failure. The symposium will take place from 6 a.m. CST to 8 a.m. CST on Monday, Nov. 10, in the Grand Ballroom of the Sheraton New Orleans Hotel.

According to the AHA, heart failure is a costly syndrome contributing to more than 3 million hospitalizations each year in the U.S. The great majority of patients with acute heart failure have fluid accumulation in the lungs (congestion) that causes shortness of breath and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women. Data from a pilot study in patients with heart failure support the expectation that these effects may be beneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring, developing a
'/>"/>

SOURCE Corthera
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
9. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
10. Symmetry Medical Reports Preliminary Third Quarter Revenue
11. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 30, 2015 , ... Noblis, Inc., a leading provider of ... published this week in the scientific journal Viruses ( http://www.mdpi.com/1999-4915/7/6/2763 ), that government ... to detect the Ebola virus. Noblis worked with the Department of Defense’s Medical ...
(Date:6/30/2015)... DIEGO , June 30, 2015  The ... Education in Biosciences (CCE/Bio) and UC San Diego ... fermentation, to be held Aug.  12 – 14, ... ).  This three-day workshop provides an intense exposure ... industrial biotechnology, and is well-suited to biologists, process ...
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate Cancer ... now offering a full suite of new genetic testing methods ... biopsy, for diagnosing prostate cancer. Dr. ... genetic tests for assessing the risk and optimizing the diagnosis ... "We,re very excited to now offer these revolutionary genetic tests ...
(Date:6/30/2015)... ... 2015 , ... Cannavoices , Inc., a premier legal ... and broadcast initiative. Produced by filmmakers, the multi-platform initiative aims to become not ... stories ever assembled. , Cannavoices profiles Advocates, Patients, Entrepreneurs, Growers, Investors, Ancillary ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... driving second new office opening in North Carolina in last 12 ... ... N.C., Jan. 17 Quintiles,Transnational Corp. today announced that the global leader ... an expansion of Quintiles, clinical research in pharmaceutical,and biotechnology development., The ...
... Board to advise on cancer screening methods and ... mitochondrial DNA-based disease detection, ... TBIO) today announced that it has formed a Scientific,Advisory ... and,scientific opportunities in cancer detection screening and mitochondrial,disease diagnosis. ...
... Advancement Towards Creating Patient-Specific and Disease-Specific ... Stem Cells For Therapeutic Use, LA ... research company, announced today it has become the,first in the world ... nuclear transfer (SCNT)., Stemagen CEO Samuel H. Wood, M.D., Ph.D., ...
Cached Biology Technology:Quintiles to Open Clinical Research Office in Wilmington, NC 2Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
(Date:6/9/2015)... 2015 Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ... "Gesture Recognition & Touchless Sensing Market by Technology ... Others), Product (Biometric & Sanitary Equipment) & by ... to their offering. The total gesture ... reach $ 23.55 Billion by 2020 at a ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... the University of Bonn, working in collaboration with scientists ... previously unknown regulatory mechanism in the process of bone ... the treatment of osteoporosis. More than four million people, ... illness in Germany alone. In recognition of the importance ...
... L-arginine following a heart attack does not improve certain ... an increased risk of death, according to a study ... is a widely available dietary supplement and is publicized ... failure and sexual dysfunction, according to background information in ...
... The discovery of a possible hibernation hormone in the ... researchers reported in the April 7, 2006 issue of ... survive unscathed--in a state of suspended animation--under the harshest ... are confirmed, the hormone would represent the first essential ...
Cached Biology News:New weapon in battle against osteoporosis 2New weapon in battle against osteoporosis 3An elephant tail 2Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3
Please email us with project details and we will respond within 24 hours to your query!...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
Request Info...
Request Info...
Biology Products: